{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:58:26Z","timestamp":1777946306119,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemostasis"],"abstract":"<jats:p>Standardized factor VIII (FVIII)-def\u03b9cient plasma is necessary for the clotting assay of this protein. Ethical considerations and prevalence of HIV seropositivity in hemophilia A patients have required the replacement of severe hemophilia A plasma by another specific substrate for FVIII clotting assays. FVIII-deficient plasma was prepared by immunodepletion using polyclonal anti-von-Willebrand factor (vWF) and monoclonal anti-FVIII antibodies coated to agarose beads. This plasma, deficient in both FVIII and vWF, allows the evaluation of FVIII activity with a detection limit of 1 % as compared to normal plasma. This immunodepleted plasma was compared to plasma from severe hemophilia A for the FVIII determination in plasma from normal subjects, severe and mild hemophiliacs, patients with von Willebrand disease and dicoumarol-treated patients. In all cases, similar values were obtained with both reagents at various levels of FVIII, with a correlation coefficient of 0.994. Such a good correlation was also obtained for the assay of FVIII in concentrates and in plasma from hemophiliacs following infusion. This immunodeficient plasma thus represents a suitable reagent for the FVIII clotting assay and provides an accurate alternative to the use of hemophilic plasma.<\/jats:p>","DOI":"10.1159\/000216145","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T09:41:27Z","timestamp":1240566087000},"page":"321-328","source":"Crossref","is-referenced-by-count":0,"title":["Preparation of Factor-VIII-Depleted Plasma with Antibodies and Its Use for the Assay of Factor VIII"],"prefix":"10.1159","author":[{"given":"C.","family":"Rothschild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Amiral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,24]]},"container-title":["Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:39:31Z","timestamp":1777739971000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216145","archive":["Portico"],"relation":{},"ISSN":["0301-0147","1423-0038"],"issn-type":[{"value":"0301-0147","type":"print"},{"value":"1423-0038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,24]]}}}